Back to top

Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Kairos Pharma, Ltd.. The associated price target remains the same w...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: